ATE341631T1 - Methode und zusammensetzung zur förderung von osteogenese - Google Patents
Methode und zusammensetzung zur förderung von osteogeneseInfo
- Publication number
- ATE341631T1 ATE341631T1 AT01966885T AT01966885T ATE341631T1 AT E341631 T1 ATE341631 T1 AT E341631T1 AT 01966885 T AT01966885 T AT 01966885T AT 01966885 T AT01966885 T AT 01966885T AT E341631 T1 ATE341631 T1 AT E341631T1
- Authority
- AT
- Austria
- Prior art keywords
- phex
- activity
- phex activity
- osteogenesis
- osteocalcin
- Prior art date
Links
- 230000011164 ossification Effects 0.000 title abstract 3
- 230000001737 promoting effect Effects 0.000 title 1
- 230000000694 effects Effects 0.000 abstract 5
- 102000004067 Osteocalcin Human genes 0.000 abstract 2
- 108090000573 Osteocalcin Proteins 0.000 abstract 2
- 210000000988 bone and bone Anatomy 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000008468 bone growth Effects 0.000 abstract 1
- 230000003292 diminished effect Effects 0.000 abstract 1
- 230000012010 growth Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000002188 osteogenic effect Effects 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24011—Neprilysin (3.4.24.11), i.e. enkephalinase or neutral endopeptidase 24.11
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
- C12N9/6494—Neprilysin (3.4.24.11), i.e. enkephalinase or neutral-endopeptidase 24.11
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/108—Osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22701200P | 2000-08-23 | 2000-08-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE341631T1 true ATE341631T1 (de) | 2006-10-15 |
Family
ID=22851392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01966885T ATE341631T1 (de) | 2000-08-23 | 2001-08-23 | Methode und zusammensetzung zur förderung von osteogenese |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7399466B2 (de) |
| EP (1) | EP1311691B1 (de) |
| JP (1) | JP2004506046A (de) |
| AT (1) | ATE341631T1 (de) |
| AU (2) | AU2001287429B2 (de) |
| CA (1) | CA2418461A1 (de) |
| DE (1) | DE60123635T2 (de) |
| WO (1) | WO2002015918A2 (de) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7105539B2 (en) | 2002-12-03 | 2006-09-12 | Enobia Pharma | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex |
| US20060292657A1 (en) * | 2003-03-26 | 2006-12-28 | Guy Boileau | Phex substrates and methods using same |
| DE602005027461D1 (de) * | 2004-04-21 | 2011-05-26 | Enobia Pharma Inc | Konjugate zur zuführung an knochen und verfahren zu deren verwendung beim hinführen von proteinen zum knochen |
| US20070081984A1 (en) | 2005-10-11 | 2007-04-12 | Shunji Tomatsu | Compositions and methods for treating hypophosphatasia |
| BR112012027765A2 (pt) | 2010-04-30 | 2019-09-24 | Enobia Pharma Inc. | métodos, composições e kits para tratamento de distúrbios de mineralização da matriz. |
| JP6055779B2 (ja) | 2010-12-27 | 2016-12-27 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | ナトリウム利尿ペプチドを含む組成物およびその使用方法 |
| US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| US10822596B2 (en) | 2014-07-11 | 2020-11-03 | Alexion Pharmaceuticals, Inc. | Compositions and methods for treating craniosynostosis |
| JP6787894B2 (ja) | 2014-12-05 | 2020-11-18 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 組換えアルカリホスファターゼを用いた発作の処置 |
| JP6868561B2 (ja) | 2015-01-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼ欠損を有する被験者を治療する方法 |
| JP6993961B2 (ja) | 2015-08-17 | 2022-01-14 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼの製造 |
| EP3355904A4 (de) | 2015-09-28 | 2019-06-12 | Alexion Pharmaceuticals, Inc. | Identifizierung wirksamer dosierungsschemata für gewebeunspezifische alkalische phosphatase-enzymersatztherapie von hypophosphatasie |
| WO2017074466A1 (en) | 2015-10-30 | 2017-05-04 | Alexion Pharmaceuticals, Inc. | Methods for treating craniosynostosis in a patient |
| WO2017155569A1 (en) | 2016-03-08 | 2017-09-14 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children |
| KR20240160671A (ko) | 2016-04-01 | 2024-11-11 | 알렉시온 파마슈티칼스, 인코포레이티드 | 알칼리성 포스파타아제로 근육 약화의 치료 |
| US10898549B2 (en) | 2016-04-01 | 2021-01-26 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
| EP3464573B1 (de) | 2016-06-06 | 2026-03-04 | Alexion Pharmaceuticals, Inc. | Auswirkungen von metallen auf die herstellung von alkalischen phosphatasen |
| EP3500289B1 (de) | 2016-08-18 | 2024-10-09 | Alexion Pharmaceuticals, Inc. | Asfotase alfa zur behandlung von tracheobronchomalazie |
| KR20190129058A (ko) | 2017-03-31 | 2019-11-19 | 알렉시온 파마슈티칼스, 인코포레이티드 | 성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법 |
| US11913039B2 (en) | 2018-03-30 | 2024-02-27 | Alexion Pharmaceuticals, Inc. | Method for producing recombinant alkaline phosphatase |
| ES2972119T3 (es) | 2018-08-10 | 2024-06-11 | Alexion Pharma Inc | Cicatrización ósea en implantes utilizando fosfatasa alcalina |
| KR20220111693A (ko) | 2019-12-09 | 2022-08-09 | 알렉시온 파마슈티칼스, 인코포레이티드 | 알칼리성 포스파타제 폴리펩티드 및 이의 이용 방법 |
| US12083169B2 (en) | 2021-02-12 | 2024-09-10 | Alexion Pharmaceuticals, Inc. | Alkaline phosphatase polypeptides and methods of use thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0739439B2 (ja) * | 1989-03-16 | 1995-05-01 | 寳酒造株式会社 | モノクローナル抗体及びその使用方法 |
| JPH05232109A (ja) * | 1990-10-04 | 1993-09-07 | Teijin Ltd | ヒト・オステオカルシンプロ蛋白の測定方法 |
| US5208219A (en) * | 1991-02-14 | 1993-05-04 | Celtrix Pharmaceuticals Inc. | Method for inducing bone growth |
| JP3894381B2 (ja) * | 1996-04-10 | 2007-03-22 | 株式会社ペプチド研究所 | 抗Ｇｌｕ▲１７▼−オステオカルシン抗体 |
| AU4107397A (en) * | 1996-09-05 | 1998-03-26 | David Goltzman | Cloning of full-length human pex cdna |
| US6413760B1 (en) * | 1997-04-15 | 2002-07-02 | Genetics Institute, Inc. | Highly purified mocarhagin cobra venom protease polynucleotides endcoding same and related proteases and therapeutic uses thereof |
| NZ506817A (en) * | 1998-02-11 | 2003-08-29 | Immunex Corp | Metalloprotease-disintegrin SVPH3-13 and SVPH3-17 nucleic acids, and their corresponding polypeptides and methods for their production |
| CA2262056A1 (en) * | 1999-02-24 | 2000-08-24 | Guy Boileau | Composition, methods and reagents for the synthesis of a soluble form of human pex |
-
2001
- 2001-08-23 CA CA002418461A patent/CA2418461A1/en not_active Abandoned
- 2001-08-23 DE DE60123635T patent/DE60123635T2/de not_active Expired - Lifetime
- 2001-08-23 WO PCT/CA2001/001220 patent/WO2002015918A2/en not_active Ceased
- 2001-08-23 AT AT01966885T patent/ATE341631T1/de not_active IP Right Cessation
- 2001-08-23 EP EP01966885A patent/EP1311691B1/de not_active Expired - Lifetime
- 2001-08-23 AU AU2001287429A patent/AU2001287429B2/en not_active Ceased
- 2001-08-23 JP JP2002520839A patent/JP2004506046A/ja active Pending
- 2001-08-23 US US10/362,259 patent/US7399466B2/en not_active Expired - Lifetime
- 2001-08-23 AU AU8742901A patent/AU8742901A/xx active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004506046A (ja) | 2004-02-26 |
| EP1311691A2 (de) | 2003-05-21 |
| DE60123635D1 (de) | 2006-11-16 |
| EP1311691B1 (de) | 2006-10-04 |
| WO2002015918A2 (en) | 2002-02-28 |
| US7399466B2 (en) | 2008-07-15 |
| WO2002015918A3 (en) | 2002-09-26 |
| CA2418461A1 (en) | 2002-02-28 |
| AU8742901A (en) | 2002-03-04 |
| US20050069569A1 (en) | 2005-03-31 |
| DE60123635T2 (de) | 2007-08-16 |
| AU2001287429B2 (en) | 2005-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE341631T1 (de) | Methode und zusammensetzung zur förderung von osteogenese | |
| ATE517996T1 (de) | Verfahren und mittel zur erhöhung der toleranz von pflanzen gegenüber stressbedingungen | |
| DE50312289D1 (de) | Verfahren zur Isolierung von mesenchymalen Stammzellen des Haarfollikels | |
| ATE458731T1 (de) | Pyrimidin-derivate zur behandlung von anormalem zellwachstum | |
| ATE287731T1 (de) | Inhibition von histondeacetylase zur behandlung von herzhypertrophie | |
| DE60132113D1 (de) | Stabilisierte zusammensetzung zum enzymatischen entfernen von wundgrind | |
| ATE424224T1 (de) | Dezellularisierung von gewebematrixen | |
| ATE241358T1 (de) | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen | |
| AR023130A1 (es) | Composiciones para promover el crecimiento | |
| DE60330161D1 (de) | Rifalazil zur behandlung von infektionen mit clostridium difficile | |
| DK1429756T3 (da) | Behandling af xanthoma med azetidinonderivater som sterolabsorptionsinhibitorer | |
| EP1802292A4 (de) | Zusammensetzungen und verfahren zur auslösung von haarwachstum | |
| DE60235545D1 (de) | Verfahren zur behandlung von nagelpilz und anderen mikrobiellen und mykotischen erkrankungen und dafür geeignete zusammensetzungen | |
| DK1427409T3 (da) | Fremgangsmåde til behandling eller forhindring af vaskulær inflammation under brug af en eller flere sterolabssorptionsinhibitorer | |
| DE602004017871D1 (de) | Zubereitungen zur behandlung von arthritischen erscheinungen | |
| DE60327557D1 (de) | Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie | |
| ATE366569T1 (de) | Verwendung von cox-2 inhibitoren als immunostimulantien zur behandlung von hiv oder aids | |
| ATE401078T1 (de) | Die verwendung von c-kithemmern zur förderung des haarwuchses | |
| ATE353667T1 (de) | Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges | |
| DE60237039D1 (de) | Verfahren zur behandlung von rosacea und telangiectasia | |
| DE60026644D1 (de) | Verwendung von Ferulasäure zur Behandlung von Bluthochdruck | |
| ATE361071T1 (de) | Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie | |
| ATE275580T1 (de) | Verfahren zur induktion der herstellung von wachstumsfaktoren | |
| ATE486609T1 (de) | Furin-hemmer zur behandlung von fibrose und narbenbildung | |
| ATE278401T1 (de) | Verwendung von riluzol zur behandlung von akustischen traumazuständen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |